In a release carried on EurekAlert (8/25), the University of Pennsylvania stated Kovanaze “was deemed safe and effective in a recent Phase 3 clinical trial led by University of Pennsylvania School of Dental Medicine researchers.”

The ADA (7/15) had reported previously that “Kovanaze™ is indicated for regional pulpal anesthesia when performing a restorative procedure on teeth 4 through 13 and A through J in adults and children who weigh 40 kg (88 lbs) or more.”